7OC0 Stock Overview
A precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
OncoCyte Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.60 |
52 Week High | US$3.78 |
52 Week Low | US$2.06 |
Beta | 0.83 |
11 Month Change | 0.78% |
3 Month Change | -3.70% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -28.63% |
Recent News & Updates
Recent updates
Shareholder Returns
7OC0 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0.8% | -3.0% | -0.1% |
1Y | n/a | -19.4% | 2.3% |
Return vs Industry: Insufficient data to determine how 7OC0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 7OC0 performed against the German Market.
Price Volatility
7OC0 volatility | |
---|---|
7OC0 Average Weekly Movement | 5.0% |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 7OC0 has not had significant price volatility in the past 3 months.
Volatility Over Time: 7OC0's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 45 | Josh Riggs | www.oncocyte.com |
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
OncoCyte Corporation Fundamentals Summary
7OC0 fundamental statistics | |
---|---|
Market cap | €36.80m |
Earnings (TTM) | -€37.37m |
Revenue (TTM) | €1.29m |
28.5x
P/S Ratio-1.0x
P/E RatioIs 7OC0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
7OC0 income statement (TTM) | |
---|---|
Revenue | US$1.38m |
Cost of Revenue | US$989.00k |
Gross Profit | US$393.00k |
Other Expenses | US$40.42m |
Earnings | -US$40.03m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.00 |
Gross Margin | 28.44% |
Net Profit Margin | -2,896.60% |
Debt/Equity Ratio | 0% |
How did 7OC0 perform over the long term?
See historical performance and comparison